1. A randomized, open‐label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. (8th August 2014) Authors: Awan, Farrukh T.; Hillmen, Peter; Hellmann, Andrzej; Robak, Tadeusz; Hughes, Steven G.; Trone, Denise; Shannon, Megan; Flinn, Ian W.; Byrd, John C.; the LUCID trial investigators Journal: British journal of haematology Issue: Volume 167:Number 4(2014:Nov.) Page Start: 466 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. (28th November 2017) Authors: Rogers, Kerry A.; Huang, Ying; Ruppert, Amy S.; Salem, Galena; Stephens, Deborah M.; Heerema, Nyla A.; Andritsos, Leslie A.; Awan, Farrukh T.; Byrd, John C.; Flynn, Joseph M.; Maddocks, Kami J.; Jones, Jeffrey A. Journal: British journal of haematology Issue: Volume 180:Number 2(2018) Page Start: 259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cardio-Oncology: A Win-Win Situation. Issue 25 (22nd December 2020) Authors: Awan, Farrukh T.; Tong, Dan; Zaha, Vlad G. Journal: Circulation Issue: Volume 142:Issue 25(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Issue 4 (3rd April 2022) Authors: Christensen, Bradley W.; Zaha, Vlad G; Awan, Farrukh T. Journal: Expert review of hematology Issue: Volume 15:Issue 4(2022) Page Start: 321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma. (13th October 2018) Authors: Hashmi, Hamza; Hamadani, Mehdi; Awan, Farrukh T. Journal: Expert opinion on pharmacotherapy Issue: Volume 19:Number 15(2018) Page Start: 1631 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort. (February 2023) Authors: Premnath, Naveen; Chung, Stephen S.; Weinberg, Olga K.; Ikpefan, Ruth; Pandey, Mohak; Kaur, Gurbakhash; Geethakumari, Praveen Ramakrishnan; Afrough, Aimaz; Awan, Farrukh T.; Anderson, Larry D.; Vusirikala, Madhuri; Collins, Robert H.; Chen, Weina; Agathocleous, Michalis; Madanat, Yazan F. Journal: Leukemia research Issue: Volume 125(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study. Issue 10 (22nd October 2022) Authors: Niemann, Carsten U.; Awan, Farrukh T.; Fogliatto, Laura; Nikitin, Eugene; Samoilova, Olga; Habib, Adel; Foroutanpour, Kayhan; Kuptsova-Clarkson, Nataliya; Opat, Stephen Journal: HemaSphere Issue: Volume 6:Issue 10(2022) Page Start: e780 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Issue 1 (March 2016) Authors: Kharfan-Dabaja, Mohamed A.; El-Asmar, Jessica; Awan, Farrukh T.; Hamadani, Mehdi; Ayala, Ernesto Journal: Baillière's best practice and research in clinical haematology Issue: Volume 29:Issue 1(2016) Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Issue 8 (3rd July 2019) Authors: Awan, Farrukh T.; Thirman, Michael J.; Patel-Donnelly, Dipti; Assouline, Sarit; Rao, Arati V.; Ye, Wei; Hill, Brian; Sharman, Jeff P. Journal: Leukemia & lymphoma Issue: Volume 60:Issue 8(2019) Page Start: 1972 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. Issue 3 (23rd February 2021) Authors: Khountham, Soun; Shindiapina, Polina; Mo, Xiaokui; Lachowiez, Curtis; Wiczer, Tracy; Mousa, Luay; Rogers, Kerry A.; Andritsos, Leslie A.; Woyach, Jennifer A.; Byrd, John C.; Spurgeon, Stephen E.; Awan, Farrukh T. Journal: Leukemia & lymphoma Issue: Volume 62:Issue 3(2021) Page Start: 716 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗